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Cardiac arrhythmias constitute a major public health problem. Pharmacological intervention 
remains mainstay to their clinical management. This in turn depends upon systematic drug 
classification schemes relating their molecular, cellular and systems effects to clinical 
indications and therapeutic actions. This approach was first pioneered in the 1960s Vaughan 
Williams classification. Subsequent progress in cardiac electrophysiological understanding 
led to a lag between the fundamental science and its clinical translation, partly addressed by 
The Working Group of the European Society of Cardiology (1991), which however did not 
emerge with formal classifications. We here utilise the recent Revised Oxford Classification 
Scheme to review anti-arrhythmic drug pharmacology. We survey drugs and therapeutic 
targets offered by the more recently characterized ion channels, transporters, receptors, 
intracellular Ca
2+ 
handling and cell signalling molecules. These are organised into their 
strategic roles in cardiac electrophysiological function. Following analysis of the arrhythmic 





 ion channels underlying depolarising and repolarising events in 
the cardiac action potential. (b) We also consider agents that modify autonomic activity that 
in turn affects both the membrane and (c) the Ca
2+
 homeostatic and excitation contraction 
coupling processes linking membrane excitation to contractile activation. Finally, we 
consider (d) drugs acting on more upstream energetic and structural remodelling processes 
currently the subject of clinical trials. Such systematic correlations of drug actions and 
arrhythmic mechanisms at different molecular to systems levels of cardiac function will 
facilitate current and future anti-arrhythmic therapy. 
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The clinical and preclinical background: Classifications of anti-arrhythmic 
drugs 
 
Cardiac arrhythmias constitute a major public health problem causing ~3.7 million deaths 
worldwide and significant clinical morbidity 
1
. Pharmacological intervention remains the 
mainstay of their management despite major progress in interventional including ablation and 
device therapy. Much of this was informed by systematic drug development and 
classification, the latter relating modes of molecular, cellular and systems actions to clinical 
indications and therapeutic effects. An early scheme classified then known anti-arrhythmic 
drugs and their actions on different components of the cardiac action potential 
2,3
. Class I 
drugs reduced phase 0 slopes and overshoots, increasing, reducing or conserving AP 





. Class II drugs slowed sino-atrial node (SAN) pacing and atrioventricular node 
(AVN) action potential conduction through β-adrenergic inhibition 
5,6
. Class III drugs 
delayed phase 3 repolarization and effective refractoriness by K
+
 channel block. Finally, 
Class IV drugs reduced cardiac, particularly SAN and AVN, rate and conduction through L-
type Ca
2+




The resulting simple yet coherent and pragmatic working model for cardiomyocyte function, 
thus approached cardiac arrhythmia in terms of disrupted cardiac electrophysiological 
activation, correlating available therapies with then known arrhythmic targets (referenced in 
7
). It found widespread usefulness in diagnostic analysis and therapeutic action, directly 
facilitating clinical management and drug development 
8
. Subsequent progress has expanded 
our electrophysiological understanding of both normal and arrhythmic cardiac excitation and 
its underlying membrane ion channel, intracellular ion transport and receptor protein 
molecules 
9,10
, and offered numerous novel pharmacological and therapeutic targets 
11
. Yet, 
management of clinical arrhythmias has often lagged progress in other cardiological areas 
and may not have optimally benefitted from these fundamental scientific advances. The latter 
may reflect unmet needs for classification of these wide-ranging findings coherently relating 
fundamental physiological mechanisms to clinical applications. This was partly attempted by 
the European Society of Cardiology 
12





Revised classifications of pharmacological anti-arrhythmic targets: The 
Modernised Oxford Classification 
 
A recent modernized classification grouped currently available approved and investigational 
new drugs through their known molecular, ion channel, transporter, receptor, intracellular 
Ca
2+ 
homeostatic or cell signalling, targets (Fig. 1A). It devised a format accomplishing a 
simultaneous classification of their actions on strategic aspects of cardiac 
electrophysiological function (Fig. 1C). Of the latter processes, (a) the altered surface 
membrane excitability disrupting normal patterns of atrial or ventricular action potential 
generation involving one or more component ion channel processes (Fig. 2) constitutes the 
immediate source of arrhythmic phenomena. However, this interacts reciprocally with 
cytosolic processes involving (b) autonomic modulation, itself acting on both (a) and (c) 
excitation contraction coupling. Drugs might also modify (d) more upstream energetic and 
remodelling structural processes often concerning cell signalling and intracellular 
metabolism, energetics and mitochondrial function, and fibrotic and inflammatory change 
(Fig. 1C).  
 
Finally, it nevertheless remained possible to pragmatically retain the original Vaughan 
Williams classes I-IV 
7
, expanding these classes and adding additional drug categories to 
complete its representation of the subsequent biomedical advance. Together with the more 
concise representation emphasizing clinically accepted as opposed to investigational new 
drugs (Table 1; 
13
), it thus represents a pragmatic modernization of the original Vaughan 
Williams approach. It retained but added to Vaughan-Williams Class I, recognising recently 
reported late Na
+
 current (INaL) components and their importance in long QT syndrome type 3 
(LQTS3). A broader Class II captures advances in our understanding of autonomic, G-protein 
signalling and an expanded Class III the many subsequently discovered K
+
 channel subtypes. 
Class IV similarly encompasses recently demonstrated molecular targets and cellular 
physiological mechanisms related to Ca
2+
 homeostasis and excitation contraction coupling. 
Further new classes recognise discoveries in cardiac automaticity (Class 0), mechanically 
sensitive channels (Class V), cell-cell electrotonic coupling (Class VI), and physiological 
processes exerting longer term energetic changes and upstream structural remodelling (Class 
VII). This classification thus categorised both clinically acceptable and potential sites of drug 
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action relevant not only to current therapy but also future basic research and drug 
development.  
 
Approved drugs, drugs under clinical trial and investigational new drugs in the 
modernized classification 
 
This scheme thus updated current views on clinically used and potential anti-arrhythmic 
agents, facilitating classification of drugs under trial, and future developments of 
investigational new drugs. This article primarily concerns drugs either impacting current 
practice or under trial for possible future practice, listed in a shortened version 
13
 of the 
scheme in the original report 
7
 in Table 1. Thus, Table 1 indicates that most drugs in Classes 
0, I, II, III and IV of the classification scheme are accepted in one or more of the American 
College of Cardiology Foundation/American Heart Association (ACCF/AHA) and National 
Institute for Clinical Excellence (NICE) guidelines for management of patients with (a) 
ventricular arrhythmias and the prevention of sudden cardiac death 
17
, (b) atrial fibrillation 
16
 
and (c) supraventricular tachycardia 
18





 Of the remainder, ranolazine (Class Id), originally approved by the U.S. Food and Drug 
Administration for anti-anginal therapy, significantly reduced AF incidence in various 
clinical settings 
22–24
, including paroxysmal AF (HARMONY trial 
25
). There are trials on use 
28
, and application  in AF cardioversion 
29
 and comparisons against amiodarone 
30,31
 of the 
K1.5 channel mediated ultrarapid K
+
 current (IKur) blocker vernakalant. Flecainide, normally 
considered part of class Ic, was trialled in relationship to management of catecholaminergic 
polymorphic ventricular tachycardia 
32–34
. Although listed, clinical trials bearing on Kir6.2 
(IKATP) openers concern anginal rather than arrhythmia management. Table 1 is simplified in 
omitting the new classes V and VI as these only include investigational as opposed to 
clinically accepted drugs.  
 
Finally, drugs in class VII are named in ACCF/AHA guidelines for management of heart 
failure 
14
 but not in ACCF/AHA guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death, atrial fibrillation and 
supraventricular tachycardia. However, there exist clinical trials testing all its drug 
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subcategories. Thus, a meta-analysis reported that both angiotensin-converting enzyme 
inhibitors (ACEIs), and angiotensin receptor inhibitors (ARBs) produced ~28% reductions in 
atrial fibrillation (AF) risk in patients with left ventricular (LV) dysfunction or hypertrophy 
35
. Clinical trials reported decreased AF in postmyocardial infarction patients with LV 
dysfunction with trandolapril 
36
, and in patients with LV dysfunction with enalapril 
37
. 
Ongoing clinical trials compared effects of telmisartan alone and in combination with 
ramipril (ONTARGET/TRANSCEND trial 
38
), and clopidogrel with irbesartan in preventing 
vascular events (ACTIVE trial 
39
). Of aldosterone receptor antagonists, a meta-analysis of 7 
reported trials of spironolactone and epleronone demonstrated reduced episodes of ventricular 
premature complexes, and 21% and 72 % reductions in sudden cardiac death and ventricular 
tachycardia 
40
. Clinical trials reported positive anti-arrhythmic effects of spironolactone in 
patients with 
42,43
 or without congestive heart failure 
47
 and of eplerenone in congestive heart 




More preliminary evidence implicates omega-3 fatty acids in reducing incidence of AF (
48
, 
but see also 
49
), particularly following coronary artery bypass surgery 
50
. Finally, a meta-
analysis suggested that 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors reduced AF 
incidence in 3 of 3 trials 
51
. Statins reduced recurrent AF in 62 retrospectively studied lone 
persistent AF (≥3 months) patients after direct current cardioversion 
52
. It lowered rate of new 
AF development in prospectively studied coronary artery patients 
53
, and AF development by 
23% in patients prospectively enrolled in the multicenter Guidant-sponsored Advancement 




Electrophysiological pro-arrhythmic mechanisms as therapeutic targets 
 
Arrhythmias are the result of abnormal sino-atrial (SA), AVN or Purkinje fibre automaticity, 
or pathological generation or conduction of excitation in atrial or ventricular cardiomyocytes. 
Sustained arrhythmia likely requires not only an initial trigger, but also arrhythmic substrate 
typically arising from re-entry of excitation from active into recovered previously active 
myocardial regions (Fig. 1B). It can take diverse forms in different cardiac regions each with 
distinct phenotypes. Successful therapeutic management of arrhythmias must therefore 
recognise this underlying mechanistic context bearing particularly upon cardiac action 






First, abnormal or altered action potential generation can arise from altered automaticity 
underlying spontaneous, rhythmic SAN, or AVN or purkinje tissue pacemaker activity. This 
could arise from altered slopes of the depolarisation processes triggering successive action 
potentials or altered maximum diastolic or resting potentials. Changes in normal automaticity 
typically reflect alterations in pacemaker potentials driven by inward HCN mediated If and 
other ionic currents following normal adrenergic or cholinergic SAN pacemaker stimulation 
or inhibition. Abnormal automaticity arises from spontaneous impulses generated in partially 
depolarised fibres in pathological circumstances; this can even involve normally non-
automatic atrial and ventricular muscle. This causes an automatic, often tachycardic, firing 
distinct from the SAN activity, exemplified by ectopic atrial tachycardias, accelerated 
idioventricular rhythms and ventricular tachycardias. 
 
Secondly, triggered activity can be initiated by membrane potential afterdepolarisation events 




 channel excitation. Early 
after-depolarisation (EAD) events typically occur under bradycardic conditions, when altered 




 and outward K
+
 current prolong the action potential. This 
permits Ca
2+
 current reactivation in turn triggering an extrasystolic action potential 
potentially leading to torsades de pointes. Delayed after-depolarisation (DAD) events 
following full action potential repolarisation result from transient inward currents, Iti, 




 exchange activity when this is increased by 
elevations in cytosolic Ca
2+






Thirdly, abnormal action potential conduction slowing can follow functional reductions in 
inward Na
+
 current initiating the action potential and driving its propagation. It can also result 
from anatomical changes altering tissue electrical resistance compromising the local circuit 
currents taking place through connexin channels, and propagating the action potential. Either 
can involve either functionally or anatomically defined pathways 
57
. Actual conduction block 
can be associated with heterogeneities in refractoriness and conduction in particular parts of 
such a circuit. These heterogeneities could be varying with time and previous impulse 
activation, or over anatomically or functionally consistent or defined paths. These often result 
in regions of unidirectional conduction block.  
 
Altered action potential conduction is then often associated with a presence of re-entrant 
substrate perpetuating previously triggered arrhythmias 
58
. Re-entry can also occur with 
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abnormal action potential recovery reflecting altered relationships between the time intervals 
between action potential recovery, refractoriness and repolarisation reserve. It has thus been 
associated with the presence of discrepancies between effective refractory periods and action 
potential recovery times as exemplified in LQT syndromes 
56
. Either spatial heterogeneities, 
exemplified by transmural gradients, or temporal heterogeneities, most frequently manifest as 




Pro-arrhythmic effects of isolated, decay or block of impulse conduction can also occur in the 
absence of re-entrant pathways. This is exemplified by the SA conduction block permitting 
escape of a supraventricular or ventricular focus then generating abnormal impulses. Similar 
phenomena could follow delayed or completely blocked AV conduction.  
 
Therapeutic targets: Ion current excitation and the action potential propagation 
wavefront  
 
The functional unit of excitable activity in the cardiomyocyte is the propagating action 
potential (Fig. 2). Typical action potential waveforms comprise rapid depolarising (phase 0), 
early repolarising (phase 1), brief atrial and prolonged ventricular plateaus (phase 2), late 
repolarisations (phase 3) and end in electrical diastole (phase 4). Phase 0 action potential 
initiation beginning this sequence of events requires inward Na
+
 current activation (Fig. 2A); 
Ca
2+
 channel activation contributes to the phase 2 plateau contribution, and is more 
prominent in ventricular than atrial muscle and is considered in the next section. Action 
potential generation through the heart is initiated from pacemaker activity in the SAN which 
possesses a If current, for which a new drug Class 0 affecting such periodic generation of 
electrical activity and therefore heart rate has been introduced. Heart rate reduction also 
offers a therapeutic strategy to managing acute cardiac ischemia.  
 
Of drugs directed at the inward Na
+
 current responsible for the depolarisation phase 0 of the 
action potential, Class Ia drugs preferentially bind to the open state of the Nav1.5 Na
+
 
channel with a dissociation time constant of τ ~1-10 s. They thus inhibit AV conduction and 
increase the effective refractory period. They also exhibit a concomitant K
+
 channel block 
which increases action potential duration. Together these properties reduce re-entrant 





channel from which they more rapidly dissociate over τ ~0.1 - 1.0 s. The latter minimises the 
duration of their actions within and through successive cardiac cycles. This explains their 
effectiveness in preventing arrhythmias in ventricular tissue, whose Na
+
 channels remain 
inactive for the longest duration amongst cardiomyocyte types reflecting the duration of the 
action potential plateau. There they block Nav1.5 window current, shortening action potential 
duration and increasing effective refractory period. They are useful in cardiac ischaemic 
situations where there is Na
+
 channel inactivation. Class Ic drugs bind to inactivated channels 
but dissociate slowly, over τ > 10 s. This results in a use-dependent channel block, 
particularly under conditions of high channel activation frequencies. They thus produce a 
generalised reduction in cardiac excitability with widespread effects, including slowing AV 
conduction, but do so whilst exerting little effect on action potential duration. Atrial Na
+
 
channels remain open for longer than in the ventricles, and so class Ia and Ic drugs have been 
used to prevent supraventricular arrhythmias 
62
.   
 
Finally, the new Class Id recognises recently developed agents acting the late Na
+
 current 
(INaL). These drugs are of potential importance for managing pro-arrhythmic situations under 
conditions of reduced repolarisation reserve as in long QT syndrome 3, and pathological 
bradycardic and ischaemic conditions, and cardiac failure. They shorten action potential 




Action potential repolarisation ultimately restoring the background resting potential is driven 
by a range of outward K
+
 currents (Fig. 2B) 
11,64
. An expanded class III reflects the 
considerable progress in our understanding of K
+
 channel subtypes 
64–68
. Thus, phase 0 
depolarisation is rapidly terminated by transient outward Kv4.3 and Kv4.2-mediated Ito 
currents driving the early phase 1 action potential repolarisation. In atrial myocytes (Fig. 2C), 
the prominent Ito and the atrial-specific Kv1.5 (KCNA5) mediated ultra-rapid IKur, as well as 
the GIRK1 and GIRK4 mediated acetylcholine sensitive IKACh together ensure the relatively 
shorter atrial action potentials. In ventricular myocytes (Fig. 2D), the Kv11.1 (HERG or 
KCNH2) mediated IKr rapidly activates with phase 0 action potential depolarisation, then 
rapidly inactivates over action potential phases 0–2 
69,70
. Phase 3 repolarisation then re-opens 
the channel driving outward phase 3 and early phase 4 currents that terminate the plateau. 
The more slowly activating Kv7.1 (KCNQ1) mediated IKs increases over phase 2 to become a 
major relatively persistent phase 3 K
+
 conductance. The Kir2.1, Kir2.2 and Kir2.3 (KCNJ2, 
KCNJ12 and KCNJ4) mediated inward rectifying IK1 reduces K
+
 conductance at voltages >-
10 
 
20 mV in phases 0-2. In contrast, it produces outward currents with repolarisation to <-40 
mV late in phase 3, and stabilises phase 4 diastolic resting potentials. The latter are also 
stabilised by background K2P2.1 (KCNK2, expressing K2P currents), and the normally small 
ATP-sensitive Kir6.2 (KCNJ11) mediating IKATP. However, the latter can be activated by 
reduced intracellular ATP levels 
71
. Finally the effective refractory period extends beyond 
each action potential. This can increase with Na
+
 channel inhibition delaying the point at 
which a critical proportion of Na
+
 channels has recovered, or with action potential 
prolongation.  
 
The new Class V of mechanosensitive channel blockers are selective for cation selective and 
a number of mechanosensitive ion channel types that include TRPC3 or TRPC6. However, 
they do not include currently clinically utilised drugs; their available exemplars are confined 
to investigational new drugs. The latter is also true for Class VI gap junction modulators, 
despite the importance of gap junction intercellular conductance between cardiomyocytes in 
cell-to-cell coupling. The latter is key to ventricular conduction, of central importance in the 
generation of re-entrant substrate. Thus, its underlying pro-arrhythmic action potential 
conduction slowing can result follow not only from compromised action potential activation 
due to reduced inward Na
+
 current but also anatomical changes altering connexin (Cx)-




Action potential depolarisation produces a coherent wave of excitation followed by 
refractoriness often propagating through often anisotropic gap junction connexin connections 
between successive SAN, atrial, AV, purkinje and endocardial and epicardial ventricular 
cardiomyocytes respectively, with detailed action potential waveforms varying with cell type. 
Thus atrial cells show shorter APs than ventricular cells, reflecting their large repolarising, 
transient outward voltage dependent and acetylcholine-sensitive K
+






 homeostasis and excitation contraction coupling. 
 
Figure 3 summarises recent reports suggesting reciprocal mechanistic relationships between 
the membrane excitation described above, and particular component excitation contraction 
coupling processes whose activation connects surface electrical activation to the initiation of 
mechanical activity. It thus represents the substantial progress made in understanding of this 
11 
 
area following Vaughan Williams’s original studies. Thus, membrane excitation includes a 
depolarisation-induced Phase 2 activation of transverse tubular L-type Ca
2+
 current ICaL in 
turn responsible for the action potential plateau phase. These Ca
2+
 currents also feed-forward 
to initiation of cardiac excitation contraction coupling. The resulting local elevations in 
cytosolic Ca
2+
concentration trigger a Ca
2+
-induced ryanodine receptor (RyR2) mediated 
sarcoplasmic reticular (SR) Ca
2+
 release, thereby synchronised to the membrane excitation 
events (Fig. 3c) 
73,74
. The resulting elevated cytosolic Ca
2+
 concentrations result in the 
troponin mediated activation of mechanical activity. Termination of this Ca
2+
 release process 
normally takes place with membrane repolarisation. The cytosolic Ca
2+
 concentration is then 











 exchanger which expels Ca
2+
 




. Thus, the 
cycles of increase followed by restoration of cytosolic Ca
2+
 concentration are normally 
synchronised with membrane events associated with the action potential. The overall 





However, the processes involved in intracellular Ca
2+
 homeostasis can show pro-arrhythmic 
events independent of such surface membrane control. They can also actually exert 
potentially pro-arrhythmic feed-back effects on their initiating membrane events. First, 
altered Ca
2+
 channel function itself may predispose to initiation of pro-arrhythmic early after-
depolarisation (EAD) phenomena late in phase 2 or early in phase 3 of the action potential 
particularly in the presence of action potential prolongation as might occur in long QT 
syndromes. These would in turn result in extrasystolic membrane excitation. Secondly, 
elevated sarcoplasmic Ca
2+
 concentrations resulting from increased Ca
2+
 channel or 
mechanosensitive channel activity, or RyR2 Ca
2+ 
sensitivity, can themselves trigger 
propagating waves of spontaneous SR Ca
2+
 release asynchronous to the normal cycles of 
membrane excitation. These can lead to elevated cytosolic Ca
2+
 concentrations. The latter can 




 exchange activity. This drives a depolarising 
transient inward current, ITI. The latter may result in pro-arrhythmic delayed after-
depolarisations (DADs) following full action potential repolarisation 
75
. Thirdly, elevations in 
cytosolic Ca
2+
 concentration have been associated with downregulated longer-term Na
+
 














These recent advances have thus considerably broadened the range of potential therapeutic 
targets concerned with such Ca
2+
 homeostasis and its modulation. They hold future promise 
of agents directed at (a) surface membrane L and/or T-type Ca
2+
 channels, (b) intracellular 
RyR and inositol trisphosphate receptor- Ca
2+
 channels, (c) SR Ca
2+





 exchange processes  and (e) phosphorylation levels of 
cytosolic Ca
2+
 handling proteins, including CamKII inhibitors and P21 activated kinase 1 
modulators. However, in this group, only Ca
2+
 channel blockers and one RyR2-blocker, 
flecainide, which has found recent use in monotherapy of catecholaminergic polymorphic 
ventricular tachycardia (CPVT) are currently clinically available. 
 
Therapeutic targets: autonomic modulators 
 
Figure 3b illustrates the various relationships between autonomic inputs and the processes 
outlined below in a retention and broadening of Vaughan Williams Class II beyond its 
originally listed sympathetic β-adrenergic effects. This reflects progress in understanding of 
the wide range of modulators acting upon the widely expressed cell surface membrane 
guanine nucleotide-binding protein (G-protein) coupled receptors (GPCRs). The latter have 
been successfully exploited in a variety of other therapeutic applications. Thus, in addition to 
the selective and non-selective adrenergic antagonists are adenosine receptor and cholinergic 
muscarinic receptor modulators 
6
, and a possibility of future potential targets amongst the 
~150 remaining orphan GPCRs. The updated G-protein mechanisms have wide actions on 
both the excitation-contraction coupling and the surface membrane groups of functions.  
 
First, β-adrenergic receptor activation produces multiple, inotropic, chronotropic and 
lusitropic effects upon cardiac function 
73
 through Gs-protein and adenylate cyclase activation 
increasing cytosolic cyclic 3’5’-adenosine monophosphate concentrations, [cAMP]i. The 
latter promotes protein kinase A (PKA) mediated phosphorylation actions on a wide range of 
ion channels including the Nav1.5 Na
+
 channel, Kv11.1 and Kv7.1 K
+
 channel species 
mediating rapid and slow IKr and IKs K
+
 currents, Cav1.2 and Cav1.3 L-type Ca
2+
 channels 
mediating ICaL and the RyR2 SR Ca
2+
 release channel. cAMP also directly enhances HCN 
13 
 
channel and consequently pacemaker If current activity. Finally, exchange proteins directly 






Secondly, of further G-protein subtypes, Table 1 now incorporates drugs targeted at Gi 
protein mediated parasympathetic cholinergic muscarinic (M2) or adenosine (A1) receptor 
activation, conversely reducing membrane excitation. These actions occur in the SAN, AVN 
or atrial myocardium even in the absence, but in ventricular tissue only in the presence, of 
pre-existing adrenergic challenge. The Gi activation causes a G protein  subunit mediated 
opening of inward rectifying IKACh or IKAdo channels particularly in supraventricular tissue, 
through actions on their GIRK1 and GIRK4 components 
65,80,81
. Gi activation also inhibits 
adenylyl cyclase reducing [cAMP]i and its associated increases in ICaL and If. It may also 





These updates prompt class II subclassifications of the clinically used nonselective and 
selective β1-adrenergic receptor inhibitors carvedilol propranolol and nadolol, and atenolol 
and bisoprolol respectively. To this are added the nonselective β-adrenergic receptor 
activators isoproterenol, reflecting the Gs-protein and adenylate cyclase modulation, and new 
subclasses also representing drugs acting through Gi protein.  
 
Possible therapeutic targets: upstream modulators of energetic status and 
structural remodeling  
 
Processes affecting long term cellular energetics and remodeling of tissue structure (Figs. 1d, 
3d) contrast with the primary pre-occupation with the acute effects on specific ion channels 
in the original Vaughan Williams classification. Thus, rather than direct effects on arrhythmic 
processes, the drugs included in Class VII are normally indicated for cardiovascular 
conditions such as hypertension, coronary artery disease, and heart failure that do not 
primarily result in arrhythmias. Nevertheless, such specific conditions, and the general 
categories of changes related to oxidative stress as well as longer term structural. fibrotic, 
hypertrophic, inflammatory, changes upstream of the electrophysiological processes at the 






Metabolic stress associated with cardiovascular conditions such as hypertrophic change, 
cardiac failure, and ischaemia-reperfusion 
87–90
, and biochemical conditions including 
obesity, insulin resistance and type 2 diabetes are thus accompanied by energetic, particularly 
mitochondrial, dysfunction 
91–93
. The consequent destabilisation of inner membrane potentials 
required to drive the electron transport chain compromises ATP synthesis. ATP depletion or 
increased ADP increases sarcolemmal ATP-sensitive K
+
 channel (sarcKATP) open 
probabilities 
94
. This shortens action potential duration, potentially producing pro-arrhythmic 
re-entrant substrate 
95,96
, and hyperpolarises cell membrane potentials compromising cell 




Compromised mitochondrial function also increases reactive oxygen species (ROS)-induced 
ROS release; ROS exert a wide range of potentially arrhythmogenic channel actions bearing 
upon cell-cell coupling 
97









 -mediated triggers 
90
. They decrease INa 
98
 and IK 
99




 and L-type Ca
2+
 channel inactivation, increase INaL and oxidise RyR2. The 
latter results in an increased SR Ca
2+









Atrial fibrosis is a potential source of arrhythmic substrate leading to atrial fibrillation; 




. A significant proportion 
of pharmacological agents that might influence this are known to act on the renin-angiotensin 
system. In the present context, rather than its immediate cardiovascular pressor effects, they 
likely relate to its effects on cardiac remodelling. Thus, angiotensin II, through angiotensin 
receptor-1 (AT1) may trigger fibroblast proliferation associated with increased transforming 
growth factor β (TGF-β) release. This promotes fibrotic and/or hypertrophic change which 
AT1 receptor antagonists are reported to reduce. Angiotensin II has also been reported to 
affect cardiac electrical activity including gap-junction mediated impulse propagation. 
Finally, AT1 receptor activation has been reported to upregulate ROS with inflammatory as 
well as mitochondrial effects. Preliminary evidence suggests that the currently available 
drugs listed including angiotensin-converting enzyme and angiotensin receptor blockers, 
aldosterone receptor antagonists, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors 






Further future upstream targets are likely to emerge. For example, the key cardiomyocyte 
regulator of ion channel activity, Ca
2+
 homeostasis and cardiac contractility 
82,83,107
, P21 
activated kinase 1 (PAK1), has been reported to cardio-protect through signalling processes 
inhibiting maladaptive, pro-arrhythmic, hypertrophic remodelling and progression in cardiac 
failure 
108





Cardiac arrhythmias constitute a major clinical problem, and pharmacological intervention 
remains the mainstay of their clinical management. Rational drug use relies on a fundamental 
understanding of drug modes of action through the cellular, systems, and clinical levels and 
clear correlations of these with their clinical indications and therapeutic actions. This thus 
further involves their systematic classification relating these scientific and clinical issues 
within a rational framework. This article surveys current clinically established anti-
arrhythmic drugs in the light of pharmacological developments that followed the historic 
Vaughan Williams classification of such agents. It utilises the major progress in our 
understanding of cardiac electrophysiology, its contained mechanisms and its molecular and 
physiological basis in the large number of underlying membrane ion channel, intracellular ion 
transport and autonomic receptor and effector protein molecules underlying normal and 
abnormal cardiac function. It places these within a recently introduced classification scheme 
systematising their pharmacological targets in the light of recent biomedical advances. The 
latter in turn are grouped into categories of electrophysiological effects and their direct or 
indirect convergence upon their primary arrhythmic mechanisms. Such a systematic approach 
may facilitate current and future anti-arrhythmic therapy. 
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Class Drug exemplars Pharmacological targets Clinical indications Therapeutic action  
0  HCN channel blockers 
 ivabradine HCN channel mediated 
pacemaker current (If) 
inhibitor. 
Stable angina and chronic cardiac failure with 





Reduced SAN automaticity 
 
I  Voltage-gated Na
+
 channel inhibitors 
 quinidine, ajmaline, 
disopyramide 
 
Nav1.5 open state; 
intermediate (τ~1-10 s) 





Supraventricular tachyarrhythmias particularly 
recurrent AF. VT, VF (including SQTS and 




Reduced ectopic ventricular/atrial automaticity and 
accessory pathway conduction. Increased refractory 
period, decreasing re-entrant tendency
19–21
 
 lidocaine, mexiletine Nav1.5 open state; rapid 
dissociation (τ~0.1-1.0 s). INa  
window current 
Ventricular tachyarrhythmias (VT, VF), 
particularly following myocardial infarction 
[ACCF/AHA/NICE guidelines 
15,17
].   
Reduced ectopic ventricular automaticity, DAD-
induced triggered activity, and re-entrant tendency by 
converting unidirectional to bidirectional block, 




 propafenone, flecainide Nav1.5 inactivated state; slow 
dissociation (τ>10 s). 
Supraventricular tachyarrhythmias (AT, Af, 
AF and tachycardias involving accessory 
pathways). Ventricular tachyarrhythmias 
resistant to other treatment in the absence of 




Reduced ectopic ventricular/atrial automaticity, DAD-
induced triggered activity, and re-entrant tendency by 
converting unidirectional to bidirectional block. 
Slowed conduction and reduced excitability 
particularly at rapid heart rates blocking re-entrant 
pathways showing depressed conduction
19–21
 
 ranolazine Nav1.5 late INaL current.  Stable angina, VT. Potential new class of 
drugs for management of tachyarrhythmias, 
particularly in LQTS3. [Clinical trials related 




Decreased AP recovery time and QT interval. Reduced 
EAD -induced triggered activity 
II  Autonomic inhibitors and activators 
26 
 














Sinus tachycardia or other types of 
tachycardic, including supraventricular (AF, 
Af, AT), arrhythmias.  Rate control of AF, and 
ventricular tachyarrhythmias (VT, PVC). 
[note. Atenolol, propranolol and nadolol also 




Reduced SAN, AVN and ectopic ventricular/atrial 
automaticity. Reduced EAD/DAD-induced triggered 






Nonselective β adrenergic 
receptor activators 
Congenital or acquired (often drug-related) 









 atropine, anisodamine, 
hyoscine, scopolamine 
Muscarinic M2 receptor 
inhibitors 
 
Mild or modulate symptomatic sinus 









 carbachol, pilocarpine, 
methacholine, digoxin 
Muscarinic M2 receptor 
activators 









 adenosine, ATP. 
[note: aminophylline acts as 
an adenosine receptor 
inhibitor] 
 




Sinus tachycardia, supraventricular 
tachyarrhythmias, frequent atrial or premature 
ventricular beats, cAMP-mediated triggered 




Reduced SAN automaticity, EAD/DAD-induced 




III   K
+
 channel inhibitors and openers 








VT in patients without structural heart disease, 
or with remote myocardial infarction, 
Tachyarrhythmias with WPW. AF with AV 
conduction via accessory pathway; VF and 
PVC; Tachyarrhythmias associated with 




Increased AP recovery time, and refractory period, 
decreasing re-entrant tendency. 





 dofetilide, ibutilide, sotalol  Kv11.1 (HERG) channel 
mediated rapid K
+
 current (IKr) 
inhibitors 
 
VT in patients without structural heart disease, 
or with remote myocardial infarction. 
Tachyarrhythmias associated with WPW 
syndrome. AF with AV conduction via 
accessory pathway, VF, PVC. Tachy-
arrhythmias associated with supraventricular 
Increased AP recovery time  and refractory period, 











 vernakalant Kv1.5 channel mediated, 
ultra-rapid K
+
 current (IKur ) 
inhibitors 
Acute conversion of AF. [Clinical trials 
related to anti-arrhythmic effects: 
28–31
] 
Increased atrial AP recovery time, and atrial refractory 




 nicorandil, pinacidil 
 
Kir6.2 (IKATP) openers 
 
Nicorandil: treatment of stable angina 
(second-line).  [note. Pinacidil: investigational 
drug for the treatment of hypertension] 
Potentially decreased AP recovery time  
 
IV   Ca
2+
 handling modulators  










Reduced AVN conduction, terminating re-entry, and  
EAD/ DAD-induced triggered activity
6,20,21
 









Supraventricular arrhythmias and VT without 




Reduced AVN conduction, terminating re-entry, and  
EAD/ DAD-induced triggered activity
6,20,21
 




Catecholaminergic polymorphic ventricular 




Reduced DAD-induced triggered activity
6,20,21
 
V  Mechanosensitive channel inhibitors 
 No clinically approved drugs 
in use. 
   
VI  Gap junction channel inhibitors 
 No clinically approved drugs 
in use. 
   
VII  Upstream target modulators  




imidapril, trandolapril,   
cilazapril 
Angiotensin-converting 
enzyme inhibitors (ACEIs) 
Management of hypertension, symptomatic 
heart failure. Potential application reducing 






Reduced structural and electrophysiological 
remodelling changes that compromise AP conduction 
and increase re-entrant tendency 






Management of hypertension, symptomatic 
heart failure. Potential application reducing 






Reduced structural and electrophysiological 
remodelling changes that compromise AP conduction 




 eplerenone, spironolactone Aldosterone receptor 
antagonists 
Congestive cardiac failure. [Clinical trials 




Potential reduction of arrhythmic substrate, including 
reduced fibrosis. K
+
 sparing diuretic effect. 






Omega-3 fatty acids Post myocardial infarct reduction of risk of 
cardiac death, myocardial infarct, stroke, and 
abnormal cardiac rhythms. [Clinical trials 
related to anti-arrhythmic effects
48–50
] 
Reduced structural and electrophysiological 
remodelling changes that compromise AP conduction 
and increase re-entrant tendency  
 statins 3-hydroxy-3-methyl-glutaryl-
CoA reductase inhibitors 
Post myocardial infarct reduction of risk of 
cardiac death, myocardial infarct, stroke, and 
abnormal cardiac rhythms. [Clinical trials 




Reduced structural and electrophysiological 
remodelling changes that compromise AP conduction 
and increase re-entrant tendency 
Notes 
1. Of categories in the full classification 
7
, Classes V (Mechanosensitive channel inhibitors), VI (Gap junction channel inhibitors) and subclasses IIIc (Transmitter dependent 
K
+
 channel inhibitors), IVc (Sarcoplasmic reticular Ca
2+
-ATPase activators), IVd (Surface membrane ion exchange inhibitors) and IVe (Phosphokinase and phosphorylase 
inhibitors) include investigational but not clinically approved drugs and are not listed here. In Class III, nicorandil and pinacidil are approved drugs but not in use or clinical 
trials for anti-arrhythmic therapy. Class VII (Upstream target modulators) contains approved drugs not in current direct use for anti-arrhythmic therapy, but for which clinical 
trials for anti-arrhythmic actions are now available. 
 
2. Abbreviations: AF, atrial fibrillation; Af, atrial flutter; AP, action potential; AT, atrial tachycardia; AV, atrioventricular; AVN; atrioventricular node; cAMP, cyclic 3’,5’-
adenosine monophosphate; CPVT, catecholaminergic polymorphic ventricular tachycardia; DAD, delayed afterdepolarisation; EAD, early afterdepolarisation; HCN, 
hyperpolarisation cyclic nucleotide activated channel; HR, heart rate; LQTS, long QT syndrome; PVC, premature ventricular contraction; SAN, sino-atrial node; SQTS, short 






Figure legends  
 
Figure 1. Modernised classification scheme 
7,13
 for currently available pharmacological 
agents directed at treatment of arrhythmia, with a correlation of the relevant classes (A) acting 
on either arrhythmic trigger or substrate 
56
 (B), to the cascade of their underlying cellular 




Figure 2. Membrane ion currents, listing their underlying proteins and encoding genes, 
underlying inward depolarising (A) or outward repolarising currents (B) producing the atrial 





Figure 3. Surface and intracellular membrane ion channels, ion exchangers, transporters, 
autonomic receptors and ionic pumps involved in cardiomyocyte physiological excitation and 
activation forming established or potential pharmacological targets underlying membrane (a) 
and autonomic signalling (b), excitation contraction coupling (c) and upstream energetic or 
structural remodelling targets (d). ACh: acetylcholine; Adr: adrenaline; cAMP: cyclic 3’5-
adenosine monophosphate; Cx: connexin; Gi: inhibitory G protein; Gs stimulatory G-protein; 






















 exchanger proteins; PKA: protein kinase A; RyR2: cardiac ryanodine 
receptor, type 2; SERCA: sarcoplasmic reticular Ca
2+
 ATPase.
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